Lifeway Foods (LWAY) said Tuesday its board rejected Danone North America's revised acquisition offer of $27 per share because it "substantially undervalues" the company.
"The board is not, however, opposed to the sale of the company at any price," the company said in a statement, explaining the rejection last week of Danone's offer.
The supplier of kefir and fermented probiotic products said its revenue has grown for 20 consecutive quarters, with gross profit increasing 92% from 2019 to 2023.
Lifeway said it expects adjusted earnings before interest, taxes, depreciation, and amortization to more than double to between $45 million and $50 million by 2027. Danone's offer implies a "very low multiple" of 7.5x to 8.5x EBITDA, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。